Introduction Developing reliable bioanalytical assays for emerging therapeutic modalities requires navigating an increasingly complex biophysical environment. When establishing analytical strategies […]
Introduction Within the highly specialized field of drug development, implementing advanced Bioanalytical Services for Rare Disease programs is essential for
Navigating Clinical Translation of CNS Small Molecules Under FDA Fast Track The clinical translation of central nervous system (CNS)-active small
Introduction: A bioanalytical method validation failure is one of the most operationally significant and regulatorily sensitive events in drug development.
Introduction: Disulfide Bond Mapping in Therapeutic Peptides is a critical analytical process used to verify the structural integrity and biological
Introduction: Why Tissue and CSF Bioanalysis Is the Defining Step in CNS Drug Development One of the greatest challenges in
Tissue and CSF Bioanalytical Services for CNS Drug Development Programs Read More »
Introduction: The Bioanalytical Complexity of ADC Programs Bioanalysis for an Antibody-Drug Conjugate Program is far from a straightforward analytical exercise.
Case Study: Dual Analyte LC-MS/MS Bioanalysis for an Antibody-Drug Conjugate Program Read More »
Introduction: Why CRO Selection Is a Regulatory Decision, Not Just a Scientific One When sponsors prepare regulated bioanalytical services for
Regulated Bioanalytical Services for NDA and BLA Submissions: What to Look for in a CRO Read More »
Introduction: The rapid expansion of GLP-1 receptor agonist therapeutics has increased the need for robust GLP-1 Biosimilar Characterization strategies. Peptide
Introduction: Why Late-Phase Bioanalysis Requires a Different Approach As a clinical development program progresses into Phase II and Phase III,
Bioanalytical CRO Services for Phase II and Phase III Clinical Trials Read More »
